Ammonium Tetrathiomolybdate (TBM)
Ammonium tetrathiomolybdate (TM) was developed as a non-toxic treatment for Wilson’s disease, which is a condition that results in copper buildup in the body. Tetrathiomolybdate binds both food copper and endogenously produced copper and prevents their absorption when taken with food. When taken without food it enters the blood and binds with available copper to prevent it being used by cells. Tetrathiomolybdate has also shown to be a promising treatment for cancer. Copper is involved in turning on the growth of new blood vessels that tumors depend on for growth. By depriving the tumors of the copper supply that is needed for new blood vessels, the growth may be slowed or stabilized. It has also been shown to target the copper transporter ATP7A and enhance the sensitivity of breast cancer to Cisplatin treatment, as well as, decreasing the development of resistance to cisplatin.